These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 33891380)

  • 1. Bimekizumab versus Secukinumab in Plaque Psoriasis.
    Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
    N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
    N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
    Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
    Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
    J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Kimball AB; Jemec GBE; Sayed CJ; Kirby JS; Prens E; Ingram JR; Garg A; Gottlieb AB; Szepietowski JC; Bechara FG; Giamarellos-Bourboulis EJ; Fujita H; Rolleri R; Joshi P; Dokhe P; Muller E; Peterson L; Madden C; Bari M; Zouboulis CC
    Lancet; 2024 Jun; 403(10443):2504-2519. PubMed ID: 38795716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
    Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
    Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA; Weinberg MA; Morris A; Reich K
    Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
    Blauvelt A; Papp KA; Merola JF; Gottlieb AB; Cross N; Madden C; Wang M; Cioffi C; Griffiths CEM
    J Am Acad Dermatol; 2020 Nov; 83(5):1367-1374. PubMed ID: 32473974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ;
    N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
    Gordon KB; Blauvelt A; Papp KA; Langley RG; Luger T; Ohtsuki M; Reich K; Amato D; Ball SG; Braun DK; Cameron GS; Erickson J; Konrad RJ; Muram TM; Nickoloff BJ; Osuntokun OO; Secrest RJ; Zhao F; Mallbris L; Leonardi CL; ; ;
    N Engl J Med; 2016 Jul; 375(4):345-56. PubMed ID: 27299809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
    Leonardi C; Matheson R; Zachariae C; Cameron G; Li L; Edson-Heredia E; Braun D; Banerjee S
    N Engl J Med; 2012 Mar; 366(13):1190-9. PubMed ID: 22455413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.
    Reich K; Körber A; Mrowietz U; Sticherling M; Sieder C; Früh J; Bachhuber T
    Br J Dermatol; 2021 May; 184(5):849-856. PubMed ID: 32652528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
    Glatt S; Helmer E; Haier B; Strimenopoulou F; Price G; Vajjah P; Harari OA; Lambert J; Shaw S
    Br J Clin Pharmacol; 2017 May; 83(5):991-1001. PubMed ID: 27859546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
    Oliver R; Krueger JG; Glatt S; Vajjah P; Mistry C; Page M; Edwards H; Garcet S; Li X; Dizier B; Maroof A; Watling M; El Baghdady A; Baeten D; Ionescu L; Shaw S
    Br J Dermatol; 2022 Apr; 186(4):652-663. PubMed ID: 34687214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
    Warren RB; Blauvelt A; Poulin Y; Beeck S; Kelly M; Wu T; Geng Z; Paul C
    Br J Dermatol; 2021 Jan; 184(1):50-59. PubMed ID: 32594522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
    Papp KA; Gooderham M; Lynde C; Brassard D; Al-Mohammedi F; Prajapati VH; Delorme I; Albrecht L; Haydey R; Alam MS; Beecker J; Siddha S; Maguin M; Farag MS; Vieira A; Rihakova L; Langley RG
    Arch Dermatol Res; 2024 Jun; 316(7):362. PubMed ID: 38850346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
    Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
    J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.